Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in recent gestational diabetes
NCT03215069Phase 3Completed
- Sponsor
- Mount Sinai Hospital
- Start
- Jul 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Insulin Secretion-Sensitivity Index-2 at 48 weeks. Started Jul 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03215069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215069.